Abstract 1486P
Background
Living with lung cancer (LC) becomes a long journey where disease consequences and treatment adverse events impact quality of life (QOL) of the patient and the caregiver. Here, HCP's and a patient organization developed and executed a personalized respiratory and physical rehabilitation pilot program for unresectable metastatic LC patients.
Methods
25 stage IV unresectable patients were recruited from a Facebook post. They received 4 physiotherapist visits, where a personalized physiotherapy program was tailored, using a personal booklet and equipment provision. All received two types of recommendations: aerobic and strength activities. The patients and caregivers also received 3 online mental support sessions. EORTC QLQ-C30 questionnaire was used at the beginning, end of the program and two months after. The physiotherapists measured the patients’ 5 repetitions sit to stand time and 10-meter walk time at the beginning and the end of the program. Significance of results was calculated with repeated measurewithin subjects T test with one way hypothesis and a confident interval of 0.95%.
Results
Significant and maintained improvement was observed in the Sit-to-stand test, from 14.9s to 12.8s, p=0.012, the 10-meter-walk test, from 0.89m/s to 1.22m/s, p=0.014, the global health status and constipation p<0.05. In addition, emotional and social functioning, fatigue symptoms and appetite loss were improved after the intervention, whereas weren't maintained two months after completion of the program. No significant change was observed in cognitive functioning, pain symptoms, dyspnea, insomnia, diarrhea and financial difficulties. Interestingly, there was high compliance from patients and caregivers to participate in the program.
Conclusions
With the limitation of low numbers of participants, our pilot program shows feasibility and efficacy of home-based rehabilitation program for LC patients. Patients’ high desire for the intervention emphasizes the unmet need. Further investigation and extended support after program completion is needed to maintain improvement.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The Israeli Lung Cancer Foundation.
Funding
The Lung Ambition Alliance.
Disclosure
S. Shilo: Financial Interests, Personal and Institutional, Advisory Board: Roche, Sanofi. D. Urban: Financial Interests, Personal, Advisory Role: Roche, Merck, Jansen, BMS, Takeda, Medison. A. Zer: Financial Interests, Personal, Invited Speaker: Roche, BMS, MSD, Takeda, Pfizer, Novartis; Financial Interests, Personal, Advisory Board: AstraZeneca, Steba, Oncohost; Financial Interests, Personal, Other, Safety Review Committee Member: Beyond Air; Financial Interests, Personal, Stocks/Shares: Nixio; Financial Interests, Institutional, Research Grant: BMS. A. Agbarya, N. Peled: Financial Interests, Personal, Advisory Role: Roche, AstraZeneca, BMS, MSD. All other authors have declared no conflicts of interest.
Resources from the same session
1574P - Medical oncology residents mentors (MORM): A target for resiliency interventions
Presenter: David Paez
Session: Poster session 10
1575P - Smoke-free policies in outdoor areas: A potential cancer prevention strategy in Spain
Presenter: Karen Ramírez Cervantes
Session: Poster session 10
1576P - Smoking and lung cancer mortality in Italian men and women: 2003-2019
Presenter: Diego Serraino
Session: Poster session 10
1577P - Indoor radon in patients with lung cancer in Spain: Preliminary data from the MIRROR study
Presenter: Marta Garcia De Herreros
Session: Poster session 10
1578P - Perception of LMIC oncologists on meaningful cancer trial endpoints and value of cancer drugs
Presenter: Soumitra Shankar Datta
Session: Poster session 10
1579P - The Dutch national adolescent and young adult (AYA) cancer care network, a data driven learning healthcare system
Presenter: Winette Van Der Graaf
Session: Poster session 10
1580P - Impact of social determinants of health (SDOH) on disparities in next-generation sequencing (NGS) testing in cancer patients (pts) in the US
Presenter: Chadi Hage Chehade
Session: Poster session 10
1581P - AI enabled intervention increased real-world guideline compliant care: Improving genomic testing and cascade genetics for women with ovarian cancer (OC)
Presenter: Premal Thaker
Session: Poster session 10
1582P - Pregnancy and miscarriage in epithelial ovarian cancer (EOC) patients harboring mutational signature of homologous recombination deficiency (HRD)
Presenter: Lorena Incorvaia
Session: Poster session 10
1583P - Trial-level surrogacy of intermediate endpoints in adjuvant or neoadjuvant use of immune checkpoint blockade
Presenter: Luís Leite
Session: Poster session 10